Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis
Por:
Müller J, Sharmin S, Lorscheider J, Ozakbas S, Karabudak R, Horakova D, Weinstock-Guttman B, Shaygannejad V, Etemadifar M, Alroughani R, Patti F, Eichau S, Prat A, Lugaresi A, Tomassini V, Kermode AG, Amato MP, Turkoglu R, Altintas A, Buzzard K, Soysal A, van der Walt A, Butzkueven H, Blanco Y, Gerlach O, Khoury SJ, Barnett M, John N, Lechner-Scott J, Foschi M, Surcinelli A, van Pesch V, Prevost J, Sa MJ, Maimone D, D'hooghe M, Hughes S, Hodgkinson S, McGuigan C, Cartechini E, Taylor B, Spitaleri D, Slee M, McCombe P, Yamout B, Benkert P, Kuhle J, Kappos L, Roos I, Kalincik T, Havrdova EK, Girard M, Duquette P, Fabis-Pedrini M, Carroll WM, Skibina O, Gouider R, Mrabet S, Ramo-Tello C, Solaro C, Habek M, Van Wijmeersch B, Ampapa R, Macdonell R, Oreja-Guevara C, de Gans K, Laureys G, Oh J, Garber J, Gray O, Agüera-Morales E, Sanchez-Menoyo JL, Castillo-Triviño T, Grigoriadis N, Petersen T, Hardy TA, Vucic S, Reddel S, Ramanathan S, Al-Asmi A, Simu M, Baghbanian SM, Poehlau D, Al-Harbi T, Rojas JI, Deri N, Lalive P, Cambron M, Csepany T, Shuey N, Willekens B, Shaw C, Decoo D, Massey J, Yaldizli Ö, Derfuss T and Granziera C
Publicada:
1 jun 2025
Ahead of Print:
1 abr 2025
Resumen:
Importance Progression independent of relapse activity (PIRA) is a significant contributor to long-term disability accumulation in relapsing-remitting multiple sclerosis (MS). Prior studies have used varying PIRA definitions, hampering the comparability of study results. Objective To compare various definitions of PIRA. Design, Setting, and Participants This cohort study involved a retrospective analysis of prospectively collected data from the MSBase registry from July 2004 to July 2023. The participants were patients with MS from 186 centers across 43 countries who had clinically definite relapsing-remitting MS, a complete minimal dataset, and 3 or more documented Expanded Disability Status Scale (EDSS) assessments. Exposure Three-hundred sixty definitions of PIRA as combinations of the following criteria: baseline disability (fixed baseline with re-baselining after PIRA, or plus re-baselining after relapses, or plus re-baselining after improvements), minimum confirmation period (6, 12, or 24 months), confirmation magnitude (EDSS score at/above worsening score or at/above threshold compared with baseline), freedom from relapse at EDSS score worsening (90 days prior, 90 days prior and 30 days after, 180 days prior and after, since previous EDSS assessment, or since baseline), and freedom from relapse at confirmation (30 days prior, 90 days prior, 30 days before and after, or between worsening and confirmation). Main Outcome and Measure For each definition, we quantified PIRA incidence and persistence (ie, absence of a 3-month confirmed EDSS improvement over >= 5 years). Results Among 87 239 patients with MS, 33 303 patients fulfilled the inclusion criteria; 24 152 (72.5%) were female and 9151 (27.5%) were male. At the first visits, the mean (SD) age was 36.4 (10.9) years; 28 052 patients (84.2%) had relapsing-remitting MS, and the median (IQR) EDSS score was 2.0 (1.0-3.0). Participants had a mean (SD) 15.1 (11.9) visits over 8.9 (5.2) years. PIRA incidence ranged from 0.141 to 0.658 events per decade and persistence from 0.753 to 0.919, depending on the definition. In particular, the baseline and confirmation period influenced PIRA detection. The following definition yielded balanced incidence and persistence: a significant disability worsening compared with a baseline (reset after each PIRA event, relapse, and EDSS score improvement), in absence of relapses since the last EDSS assessment, confirmed with EDSS scores (not preceded by relapses within 30 days) that remained above the worsening threshold for at least 12 months. Conclusion and Relevance Incidence and persistence of PIRA are determined by the definition used. The proposed standardized definition aims to enhance comparability among studies.
Filiaciones:
Müller J:
CORe, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia
Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland
Sharmin S:
CORe, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia
Lorscheider J:
Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland
Ozakbas S:
Izmir University of Economics, Medical Point Hospital, Konak/Izmir, Turkey
Multiple Sclerosis Research Association, Izmir, Turkey
Karabudak R:
Neurological Sciences - Department of Neurology Neuroimmunology Unit, Yeditepe Faculty of Medicine, Yeditepe University Hospitals, Istanbul, Turkey
Horakova D:
Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
Weinstock-Guttman B:
Department of Neurology, Jacobs MS Center for Treatment and Research, Buffalo, New York
Shaygannejad V:
Isfahan University of Medical Sciences, Isfahan, Iran
Etemadifar M:
Neurology, Dr Etemadifar MS Institute, Isfahan, Iran
Alroughani R:
Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait
Patti F:
Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania, Italy
UOS Sclerosi Multipla, AOU Policlinico "G Rodolico-San Marco," Catania, Italy
Eichau S:
Department of Neurology, Hospital Universitario Virgen Macarena, Sevilla, Spain
Prat A:
CHUM MS Center and Universite de Montreal, Montreal, Quebec, Canada
Lugaresi A:
IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italia
Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Bologna, Italy
Tomassini V:
Institute for Advanced Biomedical Technologies (ITAB), Department of Neurosciences, Imaging and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Chieti, Italy
Kermode AG:
Perron Institute for Neurological and Translational Science, University of Western Australia, Nedlands, Western Australia, Australia
Amato MP:
Department NEUROFARBA, University of Florence, Florence, Italy
IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy
Turkoglu R:
Department of Neurology, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey
Altintas A:
Department of Neurology, School of Medicine and Koc University Research Center for Translational Medicine (KUTTAM), Koc University, Istanbul, Turkey
Buzzard K:
Department of Neurosciences, Box Hill Hospital, Melbourne, Victoria, Australia
Eastern Health Clinical School, Monash University, Box Hill, Melbourne, Victoria, Australia
Soysal A:
Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey
van der Walt A:
Department of Neurology, The Alfred Hospital, Melbourne, Victoria, Australia
Butzkueven H:
Department of Neurology, The Alfred Hospital, Melbourne, Victoria, Australia
Blanco Y:
Center of Neuroimmunology, Service of Neurology, Hospital Clinic de Barcelona, Barcelona, Spain
Gerlach O:
Academic MS Center Zuyd, Department of Neurology, Zuyderland Medical Center, Sittard-Geleen, the Netherlands
School for Mental Health and Neuroscience, Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands
Khoury SJ:
Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon
Barnett M:
Brain and Mind Centre, Sydney, New South Wales, Australia
John N:
Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Department of Neurology, Monash Health, Clayton, Australia
Lechner-Scott J:
Hunter Medical Research Institute, University Newcastle, Newcastle, Australia
Foschi M:
Department of Neuroscience, MS Center, Neurology Unit, S. Maria delle Croci Hospital of Ravenna, Ravenna, Italy
Surcinelli A:
AUSL Romagna, Department of Diagnostic Imaging, S. Maria delle Croci Hospital of Ravenna, Ravenna, Italy
van Pesch V:
Department of Neurology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
Prevost J:
CSSS Saint-Jérôme, Saint-Jerome, Canada
Sa MJ:
Department of Neurology, Centro Hospitalar Universitario de Sao Joao, Porto, Portugal
Maimone D:
Centro Sclerosi Multipla, UOC Neurologia, Azienda Ospedaliera per l'Emergenza Cannizzaro, Catania, Italy
D'hooghe M:
Department of Neurology, Nationaal MS Centrum, Melsbroek, Belgium
Hughes S:
Royal Victoria Hospital, Belfast, United Kingdom
Hodgkinson S:
Immune Tolerance Laboratory Ingham Institute and Department of Medicine, University of New South Wales, Sydney, New South Wales, Australia
McGuigan C:
St Vincent's University Hospital, Dublin, Ireland
Cartechini E:
Neurology Unit, P O Unico Macerata, ast Macerata, Macerata, Italy
Taylor B:
Royal Hobart Hospital, Hobart, Australia
Spitaleri D:
Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy
Slee M:
College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia
McCombe P:
Department of Neurology, University of Queensland, Brisbane, Queensland, Australia
Yamout B:
Neurology Institute, Harley Street Medical Center, Abu Dhabi, United Arab Emirates
Benkert P:
Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland
Kuhle J:
Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland
Kappos L:
Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland
Roos I:
CORe, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia
Kalincik T:
CORe, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia
Havrdova EK:
Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
Girard M:
CHUM MS Center and Universite de Montreal, Montreal, Quebec, Canada
Duquette P:
CHUM MS Center and Universite de Montreal, Montreal, Quebec, Canada
Fabis-Pedrini M:
Perron Institute for Neurological and Translational Science, University of Western Australia, Nedlands, Western Australia, Australia
Carroll WM:
Perron Institute for Neurological and Translational Science, University of Western Australia, Nedlands, Western Australia, Australia
Skibina O:
Department of Neurosciences, Box Hill Hospital, Melbourne, Victoria, Australia
Gouider R:
Department of Neurology, LR 18SP03, Clinical Investigation Centre Neurosciences and Mental Health, Razi University Hospital, Tunis, Tunisia
Mrabet S:
Department of Neuroscience, Hospital Germans Trias i Pujol, Badalona, Spain
:
Department of Neuroscience, Hospital Germans Trias i Pujol, Badalona, Spain
Solaro C:
Department of Neurology, ASL3 Genovese, Genova, Italy
Habek M:
Department of Neurology, University Hospital Center Zagreb and University of Zagreb, School of Medicine, Zagreb, Croatia
Van Wijmeersch B:
University MS Centre, Hasselt-Pelt, Noorderhart, Rehabilitation & MS, Pelt and Hasselt University, Hasselt, Belgium
Ampapa R:
Nemocnice Jihlava, Jihlava, Czech Republic
Macdonell R:
Austin Health, Melbourne, Victoria, Australia
Oreja-Guevara C:
Department of Neurology, Hospital Clínico Universitario San Carlos, IdISSC, Madrid, Spain
de Gans K:
Groene Hart Ziekenhuis, Gouda, the Netherlands
Laureys G:
Department of Neurology, University Hospital Ghent, Ghent, Belgium
Oh J:
St Michael's Hospital, Toronto, Ontario, Canada
Garber J:
Department of Neurology, Westmead Hospital, Sydney, New South Wales, Australia
Gray O:
South Eastern HSC Trust, Belfast, United Kingdom
Agüera-Morales E:
Department of Medicine and Surgery, University Hospital Reina Sofia, Cordoba, Spain
Sanchez-Menoyo JL:
Department of Neurology, Hospital de Galdakao-Usansolo, Galdakao, Spain
Castillo-Triviño T:
Hospital Universitario Donostia, San Sebastián, Spain
Grigoriadis N:
Department of Neurology, Faculty of Medicine, AHEPA University Hospital, Thessaloniki, Greece
Petersen T:
Aarhus University Hospital, Arhus C, Aarhus, Denmark
Hardy TA:
Department of Neurology, Concord Repatriation General Hospital, Sydney, New South Wales, Australia
Vucic S:
Department of Neurology, Concord Repatriation General Hospital, Sydney, New South Wales, Australia
Reddel S:
Department of Neurology, Concord Repatriation General Hospital, Sydney, New South Wales, Australia
Ramanathan S:
Translational Neuroimmunology Group, Kids Neuroscience Centre and Brain and Mind Centre, Sydney, New South Wales, Australia
Faculty of Medicine and Health, Sydney Medical School, Concord Repatriation General Hospital, Sydney, New South Wales, Australia
Al-Asmi A:
College of Medicine & Health Sciences and Sultan Qaboos University Hospital, Sultan Qaboos University, Al-Khodh, Oman
Simu M:
Department of Neurology, Timisoara, Romania
Baghbanian SM:
Department of Neurology, Booalisina Hospital, Sari, Iran
Poehlau D:
Multiple Sclerosis Centre Kamillus-Klinik, Asbach, Germany
Al-Harbi T:
Neurology Department, King Fahad Specialist Hospital-Dammam, Khobar, Saudi Arabia
Rojas JI:
Hospital Universitario de CEMIC, Buenos Aires, Argentina
Deri N:
Department of Neurology, Hospital Fernandez, Capital Federal, Argentina
Lalive P:
Unit of Neuroimmunology, Division of Neurology, Department of Clinical Neurosciences, Geneva University Hospital, Geneva, Switzerland
Cambron M:
Neurology, Az Sint-Jan Brugge, Bruges, Belgium
Csepany T:
Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
Shuey N:
St. Vincent's Hospital, Fitzroy, Melbourne, Victoria, Australia
Willekens B:
Department of Neurology, Antwerp University Hospital, Edegem, Belgium
Translational Neurosciences Research Group, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
Shaw C:
Department of Neuroscience, Barwon Health, Geelong, Australia
Decoo D:
AZ Alma Ziekenhuis, Sijsele, Damme, Belgium
Massey J:
St. Vincent's Hospital Sydney, Sydney, New South Wales, Australia
Yaldizli Ö:
Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland
Derfuss T:
Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland
Granziera C:
Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland
Green Submitted
|